Home Newsfeeds UBS Maintains Buy on Five9, Lowers Price Target to $135

UBS Maintains Buy on Five9, Lowers Price Target to $135

UBS analyst Taylor McGinnis maintains Five9 (NASDAQ:FIVN) with a Buy and lowers the price target from $180 to $135.

byBenzinga Newsdesk

July 25, 2022

1 minute read

UBS analyst Taylor McGinnis maintains Five9 (NASDAQ:FIVN) with a Buy and lowers the price target from $180 to $135.

Barclays Initiates Coverage On Arcos Dorados Holdings with Overweight Rating, Announces Price Target of $9

By Benzinga Newsdesk

September 27, 6:16 AM

Barclays analyst Antonio Hernandez initiates coverage on Arcos Dorados Holdings (NYSE:ARCO) with a Overweight rating and announces Price Target of $9.

ARCO

Industry Comparison: Evaluating UnitedHealth Group Against Competitors In Health Care Providers & Services Industry

By Benzinga Insights

June 12, 11:00 AM

In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry…

UNH

National Health Investors Sees FY23 NFFO Per Diluted Common Share $4.28-$4.31

By Benzinga Newsdesk

November 7, 9:15 PM

2023 GuidanceThe Company's guidance range for the full year 2023, with underlying assumptions and timing of certain transactions, is set forth below: 2023 Guidance Range(in millions except per share

NHI

Barclays Maintains Underweight on UWM Hldgs, Raises Price Target to $3

By Benzinga Newsdesk

January 9, 8:46 AM

Barclays analyst Mark Devries maintains UWM Hldgs (NYSE:UWMC) with a Underweight and raises the price target from $2.5 to $3.

UWMC

UBS Maintains Buy on Five9, Lowers Price Target to $135

Related Posts

Barclays Initiates Coverage On Arcos Dorados Holdings with Overweight Rating, Announces Price Target of $9

Industry Comparison: Evaluating UnitedHealth Group Against Competitors In Health Care Providers & Services Industry

National Health Investors Sees FY23 NFFO Per Diluted Common Share $4.28-$4.31

Barclays Maintains Underweight on UWM Hldgs, Raises Price Target to $3